Showing results (201-210 of 237) with videos related to
Sort By:
Pageof 24
Diabetes, Obesity & Metabolism|March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trialClare Arnott, Jing-Wei Li, Christopher P Cannon, et al.BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR 2: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.Lancet (London, England)|June 4, 2026
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trialHiddo J L Heerspink, Meg J Jardine, Donald E Kohan, et al.Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.Global Change Biology|September 1, 2021
Stability of tropical forest tree carbon-water relations in a rainfall exclusion treatment through shifts in effective water uptake depthAlexandria L Pivovaroff, Nate G McDowell, Tayana Barrozo Rodrigues, et al.American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.Diabetes & Metabolism|February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trialJinlan Liao, Amy Kang, Chao Xia, et al.Phytopathology|November 2, 2016
Oomycete Species Associated with Soybean Seedlings in North America-Part I: Identification and Pathogenicity CharacterizationJ Alejandro Rojas, Janette L Jacobs, Stephanie Napieralski, et al.European Heart Journal. Quality of Care & Clinical Outcomes|October 27, 2022
Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational studyMin Jun, Anish Scaria, Jason Andrade, et al.Pageof 24